



Company Overview

Intellipharmaeutics International Inc. is a pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Intellipharmaeutics has developed several drug delivery systems based on this technology platforms, with a pipeline of products (some of which have received FDA approval) in various stages of development. The Company has ANDA and NDA 505 (b)(2) drug delivery product candidates in its development pipeline in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

Intellipharmaeutics Announces FDA Approval for Generic Pristiq(R)

May 10 2019, 1:00 PM EDT

Intellipharmaeutics Closes US\$1.05 Million Convertible Debenture Financing with Drs. Isa and Amina Odidi

May 7 2019, 6:15 PM EDT

Intellipharmaeutics Announces an Update in the Purdue Litigation

Apr 25 2019, 6:30 PM EDT

Stock Overview

Symbol	IPCIF
Exchange	OTCQB
Market Cap	5.84m
Last Price	\$0.2665
52-Week Range	\$0.145 - \$5.517

Investor Relations

Intellipharmaeutics International Inc.
30 Worcester Road
Toronto, ON M9W 5X2
T: 416-798-3001
investors@intellipharmaeutics.com

05/22/2019 10:44 AM EDT

Management Team

Isa Odidi, Ph.D., MBA

Chairman, CEO, Co-Chief Scientific Officer (CSO)

Amina Odidi, Ph.D.

President, COO, Co-Chief Scientific Officer (CSO)

Greg Powell, CPA - CGA

Chief Financial Officer

Patrick N. Yat, Ph.D.

Vice President, Chemistry & Analytical Services

Christian Akyempon, B.Sc. (Honors), M.Sc., MBA

Vice President, Commercial Operations

Intellipharmaeutics International Inc.

30 Worcester Road
Toronto, ON M9W 5X2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 20-F and its quarterly reports. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.